Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

2015 Genitourinary Cancers Symposium /
Metastatic prostate cancer - Interpreting negative trial results

26th - 28th Feb 2015

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 26.02.15
Views: 3645

Prof Stephane Oudard and Prof Noel Clarke

Prof Stephane Oudard (Georges Pompidou Hospital, Paris, France) and Prof Noel Clarke (The Christie Hospital, Manchester, UK) discuss the implications of negative trial results with ecancertv at ASCO GU 2015 with special focus on the following abstracts:

COMET-1: Cabozantinib versus prednisone in metastatic castration-resistant prostate cancer patients previously treated with docetaxel and abiraterone and/or enzalutamide.

COMET-2 Final analysis of COMET-2: Cabozantinib versus mitoxantrone/prednisone in metastatic castration-resistant prostate cancer patients with moderate to severe pain who were previously treated with docetaxel and abiraterone and/or enzalutamide.

Androgen deprivation therapy plus docetaxel versus ADT alone for hormone-naïve metastatic prostate cancer: Long-term analysis of the GETUG-AFU 15 phase III trial.

This programme has been supported by an unrestricted educational grant from Janssen Pharmaceutica (A Johnson & Johnson Company). 

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation